landiolol has been researched along with Shock, Cardiogenic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishii, T; Izawa, K; Kinoshita, M; Masuda, M; Onoda, T; Sato, N; Tanaka, H; Urano, A | 1 |
| Arita, Y; Hasegawa, S; Segawa, T; Yamamoto, S | 1 |
2 other study(ies) available for landiolol and Shock, Cardiogenic
| Article | Year |
|---|---|
[Chemical Stability after Mixing Continuous Infusion Drugs Used to Treat Cardiogenic Shock].
Topics: Dobutamine; Humans; Milrinone; Norepinephrine; Pharmaceutical Preparations; Shock, Cardiogenic | 2022 |
Landiolol is effective for the treatment of tachycardia-induced cardiogenic shock in patients during septic shock therapy.
Topics: Aged; Anti-Arrhythmia Agents; Diagnosis, Differential; Electrocardiography; Female; Humans; Morpholines; Shock, Cardiogenic; Shock, Septic; Tachycardia, Supraventricular; Urea | 2017 |